Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3873862 · 1 trial · 1 indication
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3873862 (Part A) | EXPERIMENTAL | LY3873862 administered orally as single dose. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3873862 (Part B) | EXPERIMENTAL | LY3873862 administered orally as multiple doses. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered orally. |
| LY3873862 (Part C) | EXPERIMENTAL | LY3873862 administered orally as multiple doses. |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| LY3873862 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation * Body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²) * Are male or female participants, including those of childbearing potential Exclusion Criteria: * Have a histor...
LY3873862 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy adult participants. The specific therapeutic indication for LY3873862 has not been disclosed.
LY3873862 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating this small molecule.
LY3873862 is in Phase 1 clinical development. One Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication.
LY3873862 has been evaluated in one Phase 1 trial, NCT05492201, titled A Study of LY3873862 in Healthy Participants. The trial enrolled 84 healthy volunteers in the United Kingdom, was randomized, double-blind, and placebo-controlled, and is now completed.
LY3873862 has no disclosed therapeutic indication. Its only reported clinical study was conducted in healthy participants rather than in patients with a specific disease, so no approved or investigational use has been announced.